Although BET-inhibitor JQ1 have been shown to attenuate MYC, CDK4/6, RelA, BTK and NF-κB target gene expression in MCL cells, could synergistically induce apoptosis of ibrutinib-resistant MCL cells and has also shown some synergistic activity, mediated by NF-kB pathway blockade, in ABC-DLBCL [156,157], this inhibitor also robustly led to BRD4 protein accumulation, which has been implicated in inadequate MYC suppression [125]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.